IPM Take
ALS survival claims carry enormous emotional weight. They should be handled with urgency, but also with discipline. AB Science says long-term masitinib analyses accepted for ENCALS suggest survival benefit and preserved quality of life in a subset of patients. That is important, but it is not the same as a new approval or a settled answer. ALS patients need therapies that extend life without simply extending dependency. The hard question is whether these analyses can support a credible regulatory and access pathway.
Executive Summary
AB Science announced that new analyses from its phase 2b/3 AB10015 masitinib clinical programme in ALS have been accepted for poster presentation at the 2026 ENCALS annual meeting. The company says masitinib treatment has been linked to a five-year survival rate of 42.3% from disease onset, compared with historical standards, and that patients with slower baseline progression had a 50% five-year survival rate. AB Science also stated that among long-term survivors reaching five years from symptom onset, 49% maintained satisfactory quality of life without mechanical support such as ventilation, gastrostomy, tracheostomy or wheelchair dependence. Additional confirmatory evidence remains necessary.
Why it matters
- Patients / advocates: Survival matters, but quality of survival matters too. ALS access debates must include function, independence and caregiver burden.
- Regulators / HTA bodies: Historical comparisons and subgroup analyses need careful scrutiny before they can support access decisions.
- Clinicians / researchers: The presentation may add to the evidence discussion, but confirmatory data will decide whether the signal is strong enough to act on.
ALS trials are never just scientific. They are moral pressure.
Patients need time, but not time stripped of speech, movement, breathing support and independence. Families need hope, but not hope built on evidence that cannot hold.
AB Science’s upcoming ENCALS presentation brings masitinib back into that difficult space. The company says long-term analyses from its ALS programme suggest survival benefit compared with historical standards, with a subset of long-term survivors maintaining quality of life without major mechanical support.
That is a meaningful claim, and it deserves attention. It also demands caution.
Historical comparisons can be useful, especially in rare and severe diseases, but they are not the same as a clean randomized prospective survival result. Subgroups can identify who might benefit most, but they can also overstate certainty if not confirmed.
The affected population is people living with ALS, especially those in earlier functional stages where intervention may still preserve independence. That matters because ALS access policy cannot focus only on whether life is extended. It must ask what kind of life is being extended and at what burden to patients and caregivers.
For IPM, this is a precision-access issue. The future of ALS therapy will depend on identifying which patients can benefit, generating evidence fast enough, and keeping quality of life central. Survival without function is not the outcome families are fighting for.
